A Nature Cancer study reported development of an Fc-optimized GITR (glucocorticoid-induced tumor necrosis factor receptor–related protein) antibody engineered to strengthen CD4 T cell and dendritic cell teamwork against tumors. Researchers describe antitumor immune gains tied to improved cellular dialogue, linking receptor targeting to enhanced coordination in the tumor microenvironment. GITR is framed as a lever for immune modulation, and the antibody design uses an Fc optimization strategy intended to improve functional engagement. The findings focus on mechanistic reinforcement of cooperative immune subsets rather than single-path checkpoint effects. The work suggests a continued pipeline for next-generation immune agonists and checkpoint-adjacent antibodies built around specific immune-cell interactions.